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INTRODUCTION
It is well known that metastasis to hilar or mediastinal lymph node, the N factor, is one of the most important determinants of prognosis after lung cancer surgery (1) (2) (3) .
However, the role of lymphadenectomy in the staging and treatment of non-small cell lung cancer (NSCLC) remains controversial. Current surgical practice varies from visual inspection of the unopened mediastinum to systemic lymph node dissection.
Systematic mediastinal lymph node dissection, as practiced by Japanese surgeons, is a much more extensive operation than that practiced by North American surgeons. Little and colleagues surveyed 729 hospitals to retrieve information on the patterns of surgical care provided to patients with NSCLC (4) . The report included more than 11,000 patients with major pulmonary resections and showed that only 57.3% of patients had any mediastinal lymph nodes removed at the time of operation.
The purposes of hilar and mediastinal lymph node dissection are accurate staging and the improvement of survival though better local control. The accurate staging is very important since several large-scale randomized trials have shown that postoperative adjuvant chemotherapy can improve the survival after surgery for NSCLC (5, 6) . There is no doubt that complete lymph node dissection is the most accurate way to stage a patient's disease and to determine which patients might benefit from adjuvant therapy.
However, the extent of lymph node removal required and the impact of mediastinal lymph node removal on survival are still controversial.
In this chapter, the impact of lymph node dissection for NSCLC on the postoperative course, namely morbidity and survival, is reviewed and discussed.
DEFFINITIONS
Although nodal staging of NSCLC should be as accurate as possible, the surgical technique for lymph node assessment varies among countries and centers. It should be Hiroshi Date 4 4 also noted that different terms are used to describe these surgical techniques. The definitions for various types of lymph node assessment were recently proposed by the council of the European Society for Thoracic Surgeons (7).
Lymph node biopsy
Only suspicious one or multiple lymph node(s) are biopsied to prove N1 or N2 disease.
No systematic nodal dissection or biopsies are performed. The procedure is performed only to document lymph node metastasis when resection is not justified ( Figure 1A ).
Lymph node sampling
One or more lymph nodes are removed without any surrounding tissue, guided by preoperative or intraoperative findings that are thought to be representative ( Figure   1B ). Systematic lymph node sampling means that a predetermined sampling of the lymph node stations is performed.
Lymph node dissection
The mediastinal tissue containing lymph nodes is dissected and removed systematically within anatomical landmarks ( Figure 1C ). In other words, all of the lymph nodes in the targeted compartment must be completely removed, as a block, together with surrounding adipose tissue (8) . In general, following lobe-specific lymph node dissection should be performed: Inclusion criteria and methodologies are quite diverse among these studies, therefore, interpretation of each study has to be made carefully.
① German study (9, 11) Inclusion criteria: resectable NSCLC based on CT Hiroshi Date This is the first prospective randomized trial comparing LNS and LND. Two hundred one patients were recruited for the study, but 32 patients were excluded from analysis due to various reasons. Somewhat LNS group included 17 patients more than LND group. About 60% of patients were node-negative pathologically in each group. There was no difference in survival between LNS and LND (p = 0.256). However, they found a borderline effect on survival (p = 0.058) in patients in patients with pN1 or single level pN2. They concluded that LND does not influence survival for patients without overt lymph node involvement but might provide benefit for patients with limited lymph node metastases.
② Japanese study (12) Inclusion criteria: peripheral NSCLC less than 2 cm, cN0 based on CT Number of patients: LNS (n = 56), LND (n = 59) Median follow-up: 65 months Survival: 5-year survival LNS (84%) ≒ LND(81%) This is a small but well designed study comparing LNS and LND for patients with clinical N0 small (less than 2 cm) NSCLC. Pathological N2 was found in 14% and 12% of LNS group and LND group respectively. Survival was similar and no significant differences in the recurrence rate or survival was seen between the two groups. They concluded that clinically evaluated peripheral NSCLC smaller than 2 cm do not require LND.
③ Chinese study (13) Hiroshi Date Although these four studies were all prospective, the Chinese study was the only one which showed survival benefit of LND and other three studies showed no significant benefit. This difference may be derived from the different inclusion criteria used in each study. One can assume that LND may provide better local control and better survival than LNS only when there is positive lymph node dissected. In other words, when there is no positive lymph node dissected, LND would never be beneficial theoretically.
Therefore, how many of the patients enrolled had positive lymph node would affect the outcome of these randomized trial comparing LNS and LND. The ratio of stage I (no lymph node involved) was about 60% in German study, 30% in Chinese study, and 80% These three figures demonstrate the differences in the surgical technique for lymph node assessment. A, lymph node biopsy. B, lymph node sampling. C, lymph node dissection.
